Financial Toxicity in Breast Implant-Associated Anaplastic Large Cell Lymphoma.
Journal
Annals of plastic surgery
ISSN: 1536-3708
Titre abrégé: Ann Plast Surg
Pays: United States
ID NLM: 7805336
Informations de publication
Date de publication:
20 Nov 2023
20 Nov 2023
Historique:
medline:
23
11
2023
pubmed:
23
11
2023
entrez:
23
11
2023
Statut:
aheadofprint
Résumé
Financial toxicity is a growing concern due to its considerable effects on medical adherence, quality of life, and mortality. The cost associated with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is substantial from diagnosis to treatment, including adjuvant therapy and surgery. This study aims to assess the prevalence of financial toxicity in BIA-ALCL patients. We performed a cross-sectional, survey-based study on women with confirmed cases of BIA-ALCL from December 2019 to March 2023. The primary study outcomes were financial toxicity measured by Comprehensive Score for Financial Toxicity (COST) score and patient-reported financial burden measured by the responses to the Evaluation of the Financial Impact of BIA-ALCL survey. Lower COST scores signify higher financial toxicity. Responses were linked to patient data extracted from the medical records. Thirty-two women treated for confirmed BIA-ALCL were included. Patients were all White and were diagnosed at a median age of 51 years (range, 41-65 years). The mean COST score was 27.9 ± 2.23. Lower COST scores were associated with receipt of radiotherapy (P = 0.033), exceeding credit card limits (P = 0.036), living paycheck to paycheck (P = 0.00027), requiring financial support from friends and family (P = 0.00044), and instability in household finances (P = 0.034). Financial toxicity is prevalent in BIA-ALCL patients and has a substantial impact on patient reported burden. Insurance denial is frequent for patients with a prior history of cosmetic augmentation. Risk assessments and cost discussions should occur throughout the care continuum to minimize financial burden.
Sections du résumé
BACKGROUND
BACKGROUND
Financial toxicity is a growing concern due to its considerable effects on medical adherence, quality of life, and mortality. The cost associated with breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is substantial from diagnosis to treatment, including adjuvant therapy and surgery. This study aims to assess the prevalence of financial toxicity in BIA-ALCL patients.
METHODS
METHODS
We performed a cross-sectional, survey-based study on women with confirmed cases of BIA-ALCL from December 2019 to March 2023. The primary study outcomes were financial toxicity measured by Comprehensive Score for Financial Toxicity (COST) score and patient-reported financial burden measured by the responses to the Evaluation of the Financial Impact of BIA-ALCL survey. Lower COST scores signify higher financial toxicity. Responses were linked to patient data extracted from the medical records.
RESULTS
RESULTS
Thirty-two women treated for confirmed BIA-ALCL were included. Patients were all White and were diagnosed at a median age of 51 years (range, 41-65 years). The mean COST score was 27.9 ± 2.23. Lower COST scores were associated with receipt of radiotherapy (P = 0.033), exceeding credit card limits (P = 0.036), living paycheck to paycheck (P = 0.00027), requiring financial support from friends and family (P = 0.00044), and instability in household finances (P = 0.034).
CONCLUSIONS
CONCLUSIONS
Financial toxicity is prevalent in BIA-ALCL patients and has a substantial impact on patient reported burden. Insurance denial is frequent for patients with a prior history of cosmetic augmentation. Risk assessments and cost discussions should occur throughout the care continuum to minimize financial burden.
Identifiants
pubmed: 37994417
doi: 10.1097/SAP.0000000000003720
pii: 00000637-990000000-00350
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest and sources of funding: none declared.
Références
Lentz R, Benson AB 3rd, Kircher S. Financial toxicity in cancer care: prevalence, causes, consequences, and reduction strategies. J Surg Oncol. 2019;120:85–92.
Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103:117–128.
Mariotto AB, Enewold L, Zhao J, et al. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev. 2020;29:1304–1312.
Gordon LG, Merollini KMD, Lowe A, et al. A systematic review of financial toxicity among cancer survivors: we can't pay the co-pay. Patient. 2017;10:295–309.
Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced by cancer survivors: a systematic review. J Natl Cancer Inst. 2017;109:djw205.
Zafar SY, Abernethy AP. Financial toxicity, part I: a new name for a growing problem. Oncology (Williston Park). 2013;27:80–1, 149.
Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29:2534–2542.
Banegas MP, Guy GP Jr., de Moor JS, et al. For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff (Millwood). 2016;35:54–61.
Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18:381–390.
Lee M, Salloum RG. Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors. J Cancer Surviv. 2016;10:534–544.
Jagsi R, Pottow JAE, Griffith KA, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol. 2014;32:1269–1276.
Delgado-Guay M, Ferrer J, Rieber AG, et al. Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. Oncologist. 2015;20:1092–1098.
Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980–986.
Asaad M, Bailey C, Boukovalas S, et al. Self-reported risk factors for financial distress and attitudes regarding cost discussions in cancer care: a single-institution cross-sectional pilot study of breast reconstruction recipients. Plast Reconstr Surg. 2021;147:587e–595e.
Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34:160–168.
Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J. 2019;39(suppl 1):S3–S13.
National Comprehensive Cancer Network. NCCN Guidelines Version 1. 2020 Breast Implant-Associated ALCL; 2020. Available at: https://www. nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed August 18, 2021.
Clemens MW, Knittel CR. Commentary on: is banning texturized implants to prevent breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) a rational decision? A meta-analysis and cost-effectiveness study. Aesthet Surg J. 2020;40:732–734.
Ha M, Ngaage LM, Zhu K, et al. Breast implant-associated anaplastic large cell lymphoma (BI-ALCL): are you covered? [published online ahead of print, 2021 Apr 15]. Aesthet Surg J. 2021;sjab177. doi:10.1093/asj/sjab177.
doi: 10.1093/asj/sjab177
de Souza JA, Yap BJ, Wroblewski K, et al. Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017;123:476–484.
de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120:3245–3253.
Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 2013;119:1257–1265.
Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119:3710–3717.
Verma V, Ludmir EB, Mesko SM, et al. Commercial insurance coverage of advanced radiation therapy techniques compared with American Society for Radiation Oncology model policies. Pract Radiat Oncol. 2020;10:324–329.
Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 2013;119:1257–1265.
Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980–986.
Lusardi A. Financial literacy: do people know the ABCs of finance? Public Underst Sci. 2015;24:260–271.
Long SK, Goin D. Large racial and ethnic differences in health insurance literacy signal need for targeted education and outreach. 2014; Urban Institute Health Policy Center and the Robert Wood Johnson Foundation. Available at: http://hrms.urban.org/briefs/literacy-by-race.html. Accessed June 1, 2023.
Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18:381–390.
Smith GL, Lopez-Olivo MA, Advani PG, et al. Financial burdens of cancer treatment: a systematic review of risk factors and outcomes. J Natl Compr Canc Netw. 2019;17:1184–1192.
Tucker-Seeley RD, Yabroff KR. Minimizing the “financial toxicity” associated with cancer care: advancing the research agenda. J Natl Cancer Inst. 2015;108:djv410.
National Comprehensive Cancer Network. NCCN Guidelines Version 1. 2020 Breast Implant-Associated ALCL; 2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed August 31, 2021.
Ha M, Ngaage LM, Zhu K, et al. Breast implant-associated anaplastic large cell lymphoma (BI-ALCL): are you covered? Aesthet Surg J. 2021;sjab177. doi:10.1093/asj/sjab177.
doi: 10.1093/asj/sjab177
Bautista-Quach MA, Nademanee A, Weisenburger DD, et al. Implant-associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules. Clin Breast Cancer. 2013;13:492–495.
U.S. Department of Labor- Employee Benefits Security Administration. 2022. Women's Health and Cancer Rights Act (WHCRA). Available at: https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/whcra. Accessed January 17, 2022.
FORCE-Facing Hereditary Cancer EMPOWERED. 2022. Women's Health & Cancer Rights Act (WHRCA) - BIA-ALCL. Available at: https://www.facingourrisk.org/privacy-policy-legal/laws-protections/womens-health-cancer-rights-act/complications-revisions/BIA-ALCL. Accessed January 17, 2022.
Centers for Medicare and Medicaid Services. 2022. Women's Health and Cancer Rights Act (WHCRA). Available at: https://www.cms.gov/CCIIO/Programs-and-Initiatives/Other-Insurance-Protections/whcra_factsheet. Accessed January 17, 2022.
Centers for Disease and Control Prevention. 1. ICD - ICD-10-CM - International Classification of Diseases, Tenth Revision, Clinical Modification. Available at: https://www.cdc.gov/nchs/icd/icd10cm.htm. Published 2021. Accessed September 1, 2021.
Guy GP Jr., Yabroff KR, Ekwueme DU, et al. Healthcare expenditure burden among non-elderly cancer survivors, 2008-2012. Am J Prev Med. 2015;49(6 Suppl 5):S489–S497.
Zafar SY, McNeil RB, Thomas CM, et al. Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. J Oncol Pract. 2015;11:145–150.
Whitney RL, Bell JF, Reed SC, et al. Predictors of financial difficulties and work modifications among cancer survivors in the United States. J Cancer Surviv. 2016;10:241–250.
Jagsi R, Hawley ST, Abrahamse P, et al. Impact of adjuvant chemotherapy on long-term employment of survivors of early-stage breast cancer. Cancer. 2014;120:1854–1862.
Khera N, Chang YH, Hashmi S, et al. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014;20:1375–1381.
Houts PS, Harvey HA, Simmonds MA, et al. Characteristics of patients at risk for financial burden because of cancer and its treatment. J Psychosoc Oncol. 1985;3:15–22.
Shankaran V, Jolly S, Blough D, et al. Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population- based exploratory analysis. J Clin Oncol. 2012;30:1608–1614.
Ng MSN, Choi KC, Chan DNS, et al. Identifying a cut-off score for the COST measure to indicate high financial toxicity and low quality of life among cancer patients. Support Care Cancer. 2021;29:6109–6117.